RBC Capital initiated coverage of BeiGene (ONC) with an Outperform rating and $312 price target RBC sees a path to robust revenue growth driven by Brukinsa’s market dominance and high-value follow-on assets in the hematology-oncology space, the analyst tells investors in a research note. BeiGene’s oncology pipeline, proven R&D capabilities, and a fast to-execution mindset are key ingredients for the company’s emerging position as a global oncology powerhouse that could drive market capitalization expansion, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene’s Strategic Positioning and Growth Potential: A Buy Recommendation by Reni Benjamin
- BeiGene to discontinue development program for ociperlimab (BGB-A1217)
- BeiGene receives positive CHMP opinion for Tevimbra
- BeiGene price target raised to $259 from $207 at Bernstein
- BeiGene’s Strong Market Position and Growth Potential: A Buy Rating by Reni Benjamin